公开(公告)号：WO2016092439A1

公开(公告)日：2016-06-16

申请号：PCT/IB2015/059369

申请日：2015-12-04

Applicant: NOVARTIS AG ,  KORTEBEIN, Patrick ,  ROOKS, Daniel ,  KLICKSTEIN, Lloyd B. ,  ROUBENOFF, Ronenn ,  GLASS, David ,  TRIFILIEFF, Estelle ,  PAPANICOLAOU, Dimitris

Inventor： KORTEBEIN, Patrick ,  ROOKS, Daniel ,  KLICKSTEIN, Lloyd B. ,  ROUBENOFF, Ronenn ,  GLASS, David ,  TRIFILIEFF, Estelle ,  PAPANICOLAOU, Dimitris

IPC: A61P21/00 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

Abstract: The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.

Abstract translation: 本发明涉及肌肉生长抑制素或激活素拮抗剂，剂量方案及其药物组合物，用于治疗肌肉减少症，特别是年龄相关的肌肉减少症。 特别是，发现肌生长抑制素或激活素拮抗剂bimagrumab在增加骨骼肌力量和功能方面有利于治疗具有肌肉减少症的老年人。

公开(公告)号：WO2016097933A1

公开(公告)日：2016-06-23

申请号：PCT/IB2015/059450

申请日：2015-12-08

Applicant: NOVARTIS AG ,  BADMAN, Michael ,  KLICKSTEIN, Lloyd B. ,  LAFFITTE, Bryan

Inventor： BADMAN, Michael ,  KLICKSTEIN, Lloyd B. ,  LAFFITTE, Bryan

IPC: A61K31/4748 ,  A61K31/497 ,  A61K31/506 ,  A61P1/16 ,  A61P1/00

CPC classification number: A61K31/439 ,  A61K31/422 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/506

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.

Abstract translation: 本发明提供使用式（I）或（II）化合物调节法呢酯X受体（FXR）的活性的方法。 特别地，本发明提供式（I）或（II）化合物或其立体异构体，对映体或其药学上可接受的盐在治疗或预防肝和胃肠道疾病中的用途。

公开(公告)号：WO2013036563A1

公开(公告)日：2013-03-14

申请号：PCT/US2012/053846

申请日：2012-09-06

Applicant: NOVARTIS AG ,  TAYLOR, Ann ,  KLICKSTEIN, Lloyd B. ,  THAKUR, Jeewan

Inventor： TAYLOR, Ann ,  KLICKSTEIN, Lloyd B. ,  THAKUR, Jeewan

IPC: A61K9/48 ,  A61K31/4196 ,  A61P5/26 ,  A61P15/08 ,  A61P35/00

CPC classification number: A61K31/4196 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.

Abstract translation: 本发明涉及包含芳香酶抑制剂4,4' - [氟 - （1-H-1,2,4-三唑-1-基）亚甲基]双苄腈作为活性成分的低剂量药物组合物， 载体。 本发明还涉及其制备方法及其作为药物的用途。

公开(公告)号：WO2009056631A2

公开(公告)日：2009-05-07

申请号：PCT/EP2008064809

申请日：2008-10-31

Applicant: NOVARTIS AG ,  ETEMAD-GILBERTSON BIJAN ,  GUILD BRAYDON CHARLES ,  KEATING MARK TAYLOR ,  KIM YONG-IN ,  KLICKSTEIN LLOYD B ,  MIKHAILOV DMITRI ,  MILIK MARIUSZ ,  ROGUSKA MICHAEL ,  SPLAWSKI IGOR ,  ZHAO KEHAO

Inventor： ETEMAD-GILBERTSON BIJAN ,  GUILD BRAYDON CHARLES ,  KEATING MARK TAYLOR ,  KIM YONG-IN ,  KLICKSTEIN LLOYD B ,  MIKHAILOV DMITRI ,  MILIK MARIUSZ ,  ROGUSKA MICHAEL ,  SPLAWSKI IGOR ,  ZHAO KEHAO

IPC: C07K16/18 ,  A61K39/395 ,  C07K7/00

CPC classification number: C07K16/18 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92

Abstract: Compositions that bind to C3b epitopes and methods of using the compositions are described herein.

Abstract translation: 本文描述了结合C3b表位的组合物和使用组合物的方法。

公开(公告)号：WO2013036562A1

公开(公告)日：2013-03-14

申请号：PCT/US2012/053844

申请日：2012-09-06

Applicant: NOVARTIS AG ,  TAYLOR, Ann ,  KLICKSTEIN, Lloyd B.

Inventor： TAYLOR, Ann ,  KLICKSTEIN, Lloyd B.

IPC: A61K9/48 ,  A61K31/4196 ,  A61P5/26 ,  A61P15/08

CPC classification number: A61K31/4196 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharmaceutical compositions comprising said aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients. Furthermore, the present invention relates to kits comprising said pharmaceutical compositions together with instructions how to administer them.

Abstract translation: 本发明涉及一种增加睾丸激素水平和用芳香酶抑制剂4,4' - [氟 - （1-H-1,2,4-三唑-1-基）亚甲基]双苄腈治疗性腺机能减退和相关疾病的方法。 本发明还涉及使用芳香酶抑制剂4,4' - [氟 - （1-H-1,2,4-三唑-1-基）亚甲基]双苄腈来增加睾丸激素水平和治疗性腺机能减退和相关疾病的方法 在特定的给药方案中。 本发明还涉及包含所述芳香酶抑制剂4,4' - [氟 - （1-H-1,2,4-三唑-1-基）亚甲基]双苄腈的药物组合物，任选与其它活性成分组合。 此外，本发明涉及包含所述药物组合物的试剂盒以及如何施用它们的说明书。

公开(公告)号：WO2009056631A3

公开(公告)日：2009-05-07

申请号：PCT/EP2008/064809

申请日：2008-10-31

Applicant: NOVARTIS AG ,  ETEMAD-GILBERTSON, Bijan ,  GUILD, Braydon Charles ,  KEATING, Mark Taylor ,  KIM, Yong-In ,  KLICKSTEIN, Lloyd B. ,  MIKHAILOV, Dmitri ,  MILIK, Mariusz ,  ROGUSKA, Michael ,  SPLAWSKI, Igor ,  ZHAO, Kehao

Inventor： ETEMAD-GILBERTSON, Bijan ,  GUILD, Braydon Charles ,  KEATING, Mark Taylor ,  KIM, Yong-In ,  KLICKSTEIN, Lloyd B. ,  MIKHAILOV, Dmitri ,  MILIK, Mariusz ,  ROGUSKA, Michael ,  SPLAWSKI, Igor ,  ZHAO, Kehao

IPC: C07K16/18 ,  A61K39/395 ,  C07K7/00

Abstract: Compositions that bind to C3b epitopes and methods of using the compositions are described herein.

公开(公告)号：IL318959A

公开(公告)日：2025-04-01

申请号：IL31895925

申请日：2025-02-11

Applicant: VERSANIS BIO INC ,  KLICKSTEIN LLOYD B

Inventor： KLICKSTEIN LLOYD B

IPC: A61K39/00 ,  C07K16/28

Abstract: Provided herein are compositions and methods for subcutaneous administration of a fixed unit dose of an ActRII antibody for disease treatment, wherein the treatment is administered across a range of subject body weights. As provided herein, the ActRII antibody fixed unit dose may include about 25 mg to about 600 mg, e.g., about 150 mg of an ActRII antibody, e.g., in a volume of about 1 ml.

公开(公告)号：CA1340866C

公开(公告)日：1999-12-28

申请号：CA595389

申请日：1989-03-31

Applicant: MAKRIDES SAVVAS C ,  WONG WINNIE W ,  CONCINO MICHAEL F ,  MARSH HENRY C JR ,  FEARON DOUGLAS T ,  IP STEPHEN H ,  KLICKSTEIN LLOYD B ,  CARSON GERALD R

Inventor： MAKRIDES SAVVAS C ,  WONG WINNIE W ,  CONCINO MICHAEL F ,  MARSH HENRY C JR ,  FEARON DOUGLAS T ,  IP STEPHEN H ,  KLICKSTEIN LLOYD B ,  CARSON GERALD R

IPC: A61K38/00 ,  A61K20060101 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  C07H20060101 ,  C07H21/04 ,  C07K1/18 ,  C07K1/22 ,  C07K14/00 ,  C07K14/315 ,  C07K14/705 ,  C07K14/715 ,  C07K16/28 ,  C12N1/21 ,  C12N5/10 ,  C12N9/70 ,  C12N9/72 ,  C12N15/09 ,  C12N15/12 ,  C12P20060101 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  C12R1/91 ,  A61K38/17 ,  C07K14/05 ,  C12N15/63

Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.